What the November 6 Amendment Changes
On November 6, Korea's Ministry of Food and Drug Safety (MFDS) published a proposed amendment to its *Regulation on Fees for Drug Approvals*, along with a proposed amendment to the *Enforcement Rule of the Advanced Regenerative Bio Act* covering advanced biologics. According to press reports, product approval fees would rise as follows:
This is a separate change from the new drug approval fee increase announced in 2024 (about KRW 410 million). That increase was aimed mainly at new synthetic drugs. This one covers biologics and data-submission drugs. Because the proposal has not been finalized, check the final notice for the effective date and any transition rules.
Why the Increase: Making Fees Match Review Costs
Since the 2024 increase, MFDS has kept moving fees closer to what reviews actually cost. The stated goals are to add reviewers, fund expedited review, and discourage "test the waters" filings submitted before the dossier is ready.
The press has reported concern that smaller pharma companies, many of whose filings are data-submission drugs, will be hit hardest. The question to watch is whether the higher fees lead to better service, such as shorter review times and more pre-submission consultations.
Start by Identifying Your Product Type
Product categories
Estimating the cost impact (illustrative)
Each data-submission drug filing would cost about KRW 13.44 million more. If you plan three such filings next year, fees alone rise by about KRW 40.32 million. Each new biologic filing would cost about KRW 12.68 million more.
To see whether other fees, such as those for variations or clinical trial approvals, are also changing, check the fee tables in the full text of the proposal.
Should You File Earlier?
The key question is whether filings received before the effective date will pay the old fee, which depends on the transition rules. Until those rules are confirmed, we do not recommend rushing every filing forward.
Reducing the Burden With Fee Reductions and Government Support
Make Your Comments Count
You can submit comments to MFDS directly or through an industry association by the deadlines (November 26 and December 16). Strong comments include:
Comments backed by numbers are more likely to influence policy than general complaints about the burden.
Prepare With KITIM
The Korea Institute of Technology Innovation Management (KITIM) can estimate the fee impact for each of your products, rework your approval timeline, review whether you qualify for fee reductions, and plan your costs around government support programs. To see how the fee changes affect your approval strategy, contact KITIM for a consultation.
